Fusion Antibodies Secures £1.17 Million in Conditional Share Placing

Fusion Antibodies Plc ( (GB:FAB) ) has issued an update.

Fusion Antibodies plc announced a conditional placing to raise approximately £1.17 million through the issuance of new ordinary shares. The funds will be used to enhance the company’s cash position, support research and development, and promote its OptiMAL® platform. The placing is divided into two tranches, with the second tranche contingent on shareholder approval at an upcoming general meeting. This financial move aims to capitalize on growth opportunities and improve the company’s market positioning, particularly in North America, while addressing the need for increased working capital.

More about Fusion Antibodies Plc

Fusion Antibodies plc operates in the biotechnology industry, specializing in pre-clinical antibody discovery, engineering, and supply for therapeutic drug and diagnostic applications. The company focuses on developing proprietary platforms like OptiMAL® and expanding its presence in key markets such as North America.

YTD Price Performance: -4.26%

Average Trading Volume: 1,226,105

Technical Sentiment Consensus Rating: Hold

Current Market Cap: £6.48M

For a thorough assessment of FAB stock, go to TipRanks’ Stock Analysis page.